Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor

Several cases of acquired resistance in patients with activating epidermal growth factor receptor (EGFR) mutation have been reported. However, rare clinical cases exist of a transformation to small cell lung cancer (SCLC) following treatment with EGFR‐tyrosine kinase inhibitors (TKIs). We report a case of non‐small cell lung cancer (NSCLC) with L858R mutation at the time of diagnosis. After failure of EGFR‐TKI therapy, we performed additional histopathologic examinations. We confirmed that the patient had a histological transformation from NSCLC to SCLC. We performed chemotherapy with etoposide and cisplatin against the SCLC and radiologic findings were improved.

• Publication year

  2014

• Venue

  Thoracic Cancer

• Publication date

  2014-12-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/1759-7714.12217PMID 26557922PMCID 4632936
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

  2013cited by this paper
• Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

  2013cited by this paper
• Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?

  2013cited by this paper
• Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

  2013cited by this paper
• Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma.

  2013cited by this paper
• Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation.

  2007cited by this paper
• Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper

• Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy

  2025cites this paper
• Whole Exome Sequencing Study Identifies Distinct Characteristics of Transformed Small Cell Lung Cancer With EGFR Mutation Compared to De Novo Small Cell and Primary Non‐Small Cell Lung Cancers

  2025cites this paper
• Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer

  2022cites this paper
• KRAS: A Druggable Target in Colon Cancer Patients

  2022cites this paper
• Agent-Based Models Help Interpret Patterns of Clinical Drug Resistance by Contextualizing Competition Between Distinct Drug Failure Modes

  2022cites this paper
• Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer

  2022cites this paper
• Outcomes in Patients With Lung Adenocarcinoma With Transformation to Small Cell Lung Cancer After EGFR Tyrosine Kinase Inhibitors Resistance: A Systematic Review and Pooled Analysis

  2022cites this paper
• Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy

  2021cites this paper
• The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer

  2019cites this paper
• Role of Cytomorphology in the Era of Liquid Biopsy

  2019cites this paper
• Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors.

  2019cites this paper
• Histological Transformation to Small Cell Carcinoma of an Adenosquamous Carcinoma of the Lung With Epidermal Growth Factor Receptor Mutation in Exons 20 and 21 After Treatment With Erlotinib: Case Report

  2019cites this paper
• Pathological transition as the arising mechanism for drug resistance in lung cancer

  2019cites this paper
• The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

  2019cites this paper
• Is transformed small cell lung cancer (SCLC) different from de novo SCLC?

  2019cites this paper
• Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: Report of a case with review of literature

  2018cites this paper
• Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors

  2018cites this paper
• Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.

  2018cites this paper
• Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives.

  2018cites this paper
• Histologic transformation of non-small-cell lung cancer in brain metastases

  2018cites this paper
• Epidermal growth factor receptor mutated oligometastatic adeno-squamous lung cancer transformation to small cell lung cancer

  2018cites this paper
• Transformation des adénocarcinomes en cancers bronchiques à petites cellules : un mode de résistance au traitement

  2017cites this paper
• Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high‐grade neuroendocrine carcinoma

  2017cites this paper
• Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma

  2017cites this paper
• Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report

  2017cites this paper
• Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.

  2017cites this paper
• Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis.

  2017cites this paper
• Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors.

  2016cites this paper
• Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases

  2016influential citation
• Stromal Expression of MicroRNA-21 in Advanced Colorectal Cancer Patients with Distant Metastases

  2016cites this paper